adagrasib

adagrasib (KRAZATI) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

KRAZATI is a marketed brand name for adagrasib. Check FDA Drugs@FDA for the current US label holder and prescribing information.

adagrasib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.